Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Invested Capital (2016 - 2025)

VYNE Therapeutics' Invested Capital history spans 10 years, with the latest figure at $27.8 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 46.69% year-over-year to $27.8 million; the TTM value through Dec 2025 reached $27.8 million, down 46.69%, while the annual FY2025 figure was $27.8 million, 46.69% down from the prior year.
  • Invested Capital reached $27.8 million in Q4 2025 per VYNE's latest filing, down from $38.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $127.9 million in Q1 2021 to a low of $11.5 million in Q3 2023.
  • Average Invested Capital over 5 years is $55.2 million, with a median of $48.6 million recorded in 2021.
  • Peak YoY movement for Invested Capital: tumbled 71.29% in 2023, then surged 452.26% in 2024.
  • A 5-year view of Invested Capital shows it stood at $48.6 million in 2021, then tumbled by 35.85% to $31.2 million in 2022, then skyrocketed by 184.39% to $88.7 million in 2023, then tumbled by 41.3% to $52.1 million in 2024, then plummeted by 46.69% to $27.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Invested Capital are $27.8 million (Q4 2025), $38.9 million (Q2 2025), and $44.1 million (Q1 2025).